Author/Authors :
Bijani Ali نويسنده Non-Communicable Pediatric Diseases Research Center, Babol University of Medical Sciences, Babol, Iran , Mahmoodi Nesheli Hassan نويسنده Non- Communicable Pediatric Disease Research Center, Babol University of Medical Sciences, Babol, Iran , Hadizadeh Amereh نويسنده
Abstract :
Background: Inhibitory antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII.Methods: From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children’s Hospital were evaluated. Those who had abnormal mixing study, antibody against FVIII were measured. Data were collected and analyzed. Results: The age range of the patients was 4-60 years. The inhibitor antibody was seen in 9 (17.3%) patients. The mean age of patients with inhibitor at the time of diagnosis was 10.22 years (ranged 4-31 years). Old patients had more hemarthrosis than young patients. The mean level of inhibitor antibody was 8.47 Bethesda (ranged 2.3-29). Six patients had inhibitor antibody level ?5 Bethesda unit and three patients had inhibitor antibody level<5 Bethesda unit.Conclusion: This study showed that the prevalence of inhibitor antibody in young patients is more than the old patients.
